Akeso and Summit’s lung cancer candidate shows worsening tumor progression, while Europe halts Tavneos over trial concerns

Akeso Therapeutics and Summit Therapeutics reported that their combined lung cancer therapy failed to improve outcomes, with data indicating a worsening in tumor progression compared to control.

The negative readout raises concerns about the drug’s efficacy and may affect ongoing development plans.

In parallel, European regulators have withdrawn the approval of Tavneos after raising questions about trial integrity, and pricing issues have been highlighted for AstraZeneca’s hypertension medication.

These developments underscore heightened scrutiny of biotech products in Europe and could influence investor sentiment across the sector.